Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Georges Francois Leclerc
10 participants will receive a cone beam computed tomography (CBCT) repositioning, while the other 10 will receive a kV imaging of fiducial marker repositioning. The principal objective is to evaluate and compare the dose received by the prostate using two repositioning techniques.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
male \> 18 years
carcinoma of the prostate histologically confirmed
OMS 0-1
localized stage
favorable, intermediate and unfavorable groups according to NCCN or D'Amico classification
patients must have signed a written informed consent form
patients must be affiliated to a Social Health Insurance.
You may not be if
metastasis
indication for pelvic radiation
anticoagulant therapy
lateral or bilateral hip replacement
patient receiving an adult protective services
Patient unable to comply with the required medical follow-up for geographic, social or psychological reasons
Clareo Health | Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer
